In vitro experiments confirmed that treatment of osteosarcoma cells with FGF-23 increased LOXL2 mRNA and protein expression in a dose-dependent manner, while the effects on LOXL1 and LOXL3 were comparatively limited. This evidence concerns the gene LOXL3 and osteosarcoma.